Want to see INSP full AI Analyst Report?
INSP Stock Chart & Stats
$49.19
$1.78(3.62%)
At close: 4:00 PM EDT
$49.19
$1.78(3.62%)
Day’s Range― - ―
52-Week Range$38.91 - $147.03
Previous CloseN/A
Volume140.99K
Average Volume (3M)998.72K
Market Cap
$1.47B
Enterprise Value$1.23K
Total Cash (Recent Filing)$283.83M
Total Debt (Recent Filing)$29.55M
Price to Earnings (P/E)11.5
Beta0.61
Next Earnings
Aug 03, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.53
Shares Outstanding28,813,152
10 Day Avg. Volume718,491
30 Day Avg. Volume998,719
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$51.17Price Target Upside4.02% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)0.9
Revenue Forecast (FY)$843.33M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Improving ProfitabilitySustained gross margins above ~85% provide structural leverage as volumes scale, enabling strong contribution margins to absorb SG&A and R&D. The shift to positive TTM net and operating margins supports durable cash generation and reinvestment capacity, underpinning long-term financial resilience.
Conservative Balance Sheet And Cash BufferA cash-rich, low-leverage balance sheet (no debt and substantial cash) gives management flexibility to fund trials, subsidize reimbursement efforts, or smooth operations through reimbursement cycles without reliance on external financing, materially reducing solvency risk over the medium term.
Robust Clinical Evidence And Large Installed BaseA sizable treated patient base and advancing large clinical studies strengthen clinical credibility and payer discussions, creating durable adoption drivers. Strong evidence and publications increase clinician trust, support reimbursement arguments, and raise switching costs for competitors over time.
Bears Say
Coding And Reimbursement AmbiguityPersistent coding ambiguity materially slows case approvals and revenue recognition, forcing manual prior authorization workflows. Because a permanent CPT solution isn't expected until 2028, this structural uncertainty can depress procedure volumes, lengthen sales cycles, and constrain durable revenue growth.
WISER Prior-authorization Pilot Reduces ThroughputAn external prior-authorization program that delays approvals directly reduces procedures and cash collection. Because this is a systemic payer-administered process, it can persist across quarters and impair revenue visibility and utilization of field resources, pressuring medium-term growth and planning.
Adverse Market Dynamics: GLP-1s And Competitor PresenceBroader trends like growing GLP-1 therapy adoption and new commercial competitors can structurally reduce the pool of surgical candidates and slow referral growth. These shifts may compress long-term addressable market growth and require sustained commercial adaptation to preserve procedure volumes.
Inspire Medical Systems News
INSP FAQ
What was Inspire Medical’s price range in the past 12 months?
Inspire Medical lowest stock price was $38.91 and its highest was $147.03 in the past 12 months.
What is Inspire Medical’s market cap?
Inspire Medical’s market cap is $1.47B.
When is Inspire Medical’s upcoming earnings report date?
Inspire Medical’s upcoming earnings report date is Aug 03, 2026 which is in 3 days.
How were Inspire Medical’s earnings last quarter?
Inspire Medical released its earnings results on May 04, 2026. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.375.
Is Inspire Medical overvalued?
According to Wall Street analysts Inspire Medical’s price is currently Undervalued.
Does Inspire Medical pay dividends?
Inspire Medical does not currently pay dividends.
What is Inspire Medical’s EPS estimate?
Inspire Medical’s EPS estimate is -0.24.
How many shares outstanding does Inspire Medical have?
Inspire Medical has 28,813,152 shares outstanding.
What happened to Inspire Medical’s price movement after its last earnings report?
Inspire Medical reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -12.017%.
Which hedge fund is a major shareholder of Inspire Medical?
Currently, no hedge funds are holding shares in INSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.17 (4.02% Upside)
$51.17 (4.02% Upside)
Blogger Sentiment
Bullish
INSP Sentiment 67%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.71%
Trailing 12-Months
Company Description
Inspire Medical
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
INSP Company Deck
INSP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral — The company delivered modest revenue growth, margin expansion, stronger operating cash flow, a solid cash position, and meaningful clinical progress, but faces material near-term headwinds from coding and reimbursement uncertainty and the WISER pilot that prompted a significant revenue guide reduction and short-term profitability pressure. Management outlined actions to mitigate the disruption (education, field reimbursement hiring, inventory strategy, targeted investments) and expects improvement later in 2026, while a permanent coding solution (new CPT) is not expected until 2028.View all INSP earnings summariesINSP Revenue Breakdown
97.02% U.S.
2.98% Other
INSP Stock 12 Month Forecast
Average Price Target
$51.17
▲(4.02% Upside)
Technical Analysis
Ownership Overview
1.71% Insiders
28.73% Mutual Funds
3.71% Other Institutional Investors
37.86% Public Companies and
Individual Investors